Clinical trial NCT05483816: MultiSENSory Stimulation to TArgeT Sensory Loss and ChronIc Pain in NeurOpathic PatieNts
Official title: MultiSENSory Stimulation to TArgeT Sensory Loss and ChronIc Pain in NeurOpathic PatieNts
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Neuropathy
Neuropathy, Painful
Sensory Neuropathy
Diabetic Neuropathies
Amputation
Lead sponsor: ETH Zurich
Sponsor class: OTHER
Collaborators: name: Neural Control of Movement laboratory ETH Zurich
First posted: 2022-08-02
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Neuropathy is a costly and disabling health issue, which consists of a degeneration of the peripheral nerves. Even though the causes may be different, such as diabetes or amputation, the consequences for neuropathic patients are multiple and extremely debilitating. Among the alarming symptoms it implicates, chronic pain and sensory loss are among the most severe ones. Because of the loss of sensations, patients are forced to have an altered gait strategy, an impaired balance and a fivefold increased risk of falling. Furthermore, since they lose sensations and feel numbness in their extremity, they are discouraged in walking, hence leading to a sedentary lifestyle. All of this is worsened by the development of neuropathic pain, which has a high comorbidity with psychological issues, such as depression and anxiety.

Today, proper treatments for neuropathic pain that exclude pharmacological solutions are still missing. This is due to the complexity of the neurobiological mechanisms underlying the origin of neuropathy, the multifaceted physical and psychological nature of pain and the lack of reliable biomarkers.

The aim of this project is to tackle the major problems connected to neuropathy thanks to non-invasive stimulation of the peripheral nervous system. The system is composed of an insole with pressure sensors that captures in real time the force exerted by the subject on the foot and couples this information with parameters of electrical stimulation. Thanks to optimal electrode placement and intensity modulation, subjects are able to perceive in real-time in a somatotopic manner (i.e., under their foot) how they are walking. The aim now is twofold: first the investigators want to couple this stimulation with Virtual Reality (VR) to develop a neuroadaptive non-invasive brain computer interface (BCI) to treat pain and secondly the investigators want to measure through fMRI scans whether the use of the sensory feedback system allows any beneficial plastic changes in the brain. Finally, the investigators want to measure through fMRI scans whether the use of the sensory feedback system allows any beneficial plastic changes in the brain.

Detailed description: One of the notoriously hardest and long-established challenges for the whole scientific community concerns the complete understanding and, consequently, the treatment of neuropathy. This condition results in an altered gait strategy, an impaired balance and a fivefold increased risk of falling. Falling is one of the major health-related problems. In the United Kingdom, more than one fourth of accidents requiring hospital treatment are a consequence of falls. Furthermore, since they lose sensations and feel numbness in their extremity, they are discouraged in walking, hence leading to a sedentary lifestyle (which promotes other long-term complications, e.g. of the cardiovascular system). This has also very severe impacts on the patients' psychological health. Indeed, the comorbidity of neuropathy with anxiety and depression has been estimated to be 59% in the U.S population. Patients may develop neuropathic pain, associable to the aberrant sensory inputs. Experiencing pain impacts even more on gait stability and on the fear of falling. Given the complexity of the underlying mechanisms, chronic neuropathic pain is one of the most prevalent, costly and disabling health issue, hitting a huge portion of the world population. Chronic pain, indeed is estimated to affect approximately 19% of the adult European population. Nowadays, current chronic pain therapies (either behavioural, pharmacological or surgical) are inefficient, as demonstrated by the high prevalence, low rates of functional recovery and the assiduous reliance on opioid analgesics.

The reasons of such lack of efficacy can be attributed to different factors, among which the lack of therapies addressing the multidimensions of pain, as pain is not a unitary phenomenon, rather a multidimensional outcome of sensory-discriminative and motivational-affective components, that should be synergistically accounted for, and the lack of reliable biomarkers: objective indicators of pain are needed to demonstrate therapeutic target engagement, to stratify patients and to predict disease progression or therapeutic responses.

These factors are the main focuses of this study, whose aim is to develop a multisensory platform for pain, detecting pain through physiological recordings and delivering a therapy when such physiological biomarkers are detected. First the detection of pain is exploited through electrophysiology and then the therapy is delivered by means of Virtual Reality (VR) and Transcutaneous Electrical Nerve Stimulation (TENS), in order to target both physiological and affective/cognitive components of neuropathic pain. VR and TENS have already singularly produced encouraging results in literature\[26-29\]. However, these results are conflicting and not conclusive. The investigators believe that the combination of these technologies, which targets all the different aspects of pain, will really provide a successful and lasting benefit to the patients chronic pain.

Furthermore, the nature of the platform, which includes the use of non-invasive electrical stimulation, allows to recreate sensations in parts of the body where the subjects don't feel sensations anymore. Indeed, thanks to years of research, the Neuro-engineering laboratory found optimal stimulation parameters and electrode placement which are able to elicit sensations far from the electrodes placement. Electrodes are indeed placed on healthy parts of the nerves, but the perceived sensation is in the extremities. This allows to target also another extremely common consequence of neuropathy: sensory loss. This symptom forces patients to have an altered gait strategy, impaired balance and a five-fold increased risk of falling. Therefore, in this study the investigators will monitor also the potential benefits of the platform on these aspects.

As for the imaging sessions, before starting the imaging sessions, patients will be assessed to obtain potential information that might impact on the results.

Healthy participants and patients will be asked to participate in two-three fMRI sessions. Prior to the scanning, a calibration procedure will take place, to understand the subject's stimulation parameters and characterize the location and type of sensations elicited.

During the fMRI sessions, the investigators will examine the neural correlates of the referred perceptions and any pain relief induced using the non-invasive TENS stimulation approach. During these sessions different types of stimulations will be performed (with the TENS stimulation system, with vibrotactile stimulators, and with visual stimulations). Resting state fMRI will be used to examine functional connectivity between different regions of interest. Each fMRI session will last \~70-80 minutes.

Eligibility criteria: for healthy:

* Inclusion:

  * Age 18-80
  * Visual acuity\&gt;6 on Snellen visual acuity chart
* Exclusion:

  * Pregnancy
  * Cognitive deficits (Mini Mental State Examination\&lt;23)
  * Cyber-sickness
  * Prior or current psychological diseases
  * Pacemakers
  * Epilepsy
  * Claustrophobia
  * Other MRI contraindications
  * Unhealed fractures
  * Unhealed wounds
  * Cancerous growth in proximity to feet
  * Swollen, infected or inflamed areas on feet or skin eruptions on feet such as phlebitis, thrombophlebitis or varicose veins

for patients:

* Inclusion:

  * Age 18-80
  * Visual acuity\&gt;6 on Snellen visual acuity chart
  * Diagnosis of peripheral neuropathy
  * Pain in lower limbs\&gt;=3 cm on VAS scale
* Exclusion:

  * Pregnancy
  * Relevant comorbidities that would affect the outcomes of the study (by judgement of physicians)
  * Ulcers
  * Cognitive deficits (Mini Mental State Examination\&lt;23)
  * Cyber-sickness
  * Prior or current psychological diseases
  * Pacemakers
  * Epilepsy
  * Claustrophobia
  * Other MRI contraindications
  * Unhealed fractures
  * Unhealed wounds
  * Cancerous growth in proximity to feet

Primary outcomes:
measure: Change in pain level
timeFrame: Through study completion, up to 10 days
measure: Changes in brain activity and connectivity through functional Magnetic Resonance Imaging (fMRI) before and after the treatment
timeFrame: baseline and 1 week follow-up
measure: Changes in brain activity and connectivity through functional Magnetic Resonance Imaging (fMRI) between somatotopic and non somatotopic stimulation at feet
timeFrame: baseline, pre-intervention
Secondary outcomes:
measure: Changes in EEG
timeFrame: Through study completion, up to 10 days
measure: Changes in Skin Conductance signatures
timeFrame: Through study completion, up to 10 days
measure: Percentage of session completed
timeFrame: post-intervention
measure: Changes in Anxiety and Depression
timeFrame: baseline, post-intervention
measure: Changes in Quality of life
timeFrame: baseline, post-intervention
measure: changes in balance
timeFrame: baseline, during the intervention, post-intervention
measure: changes in the speed to perform the Timed Up and Go (TUG) test
timeFrame: baseline, during the intervention, post-intervention
measure: changes in the ankle dorsiflexion angle is derived from gait analysis
timeFrame: baseline, during the intervention, post-intervention
measure: changes in speed and cadence in the 10 meter and 6 min walk test
timeFrame: baseline, during the intervention, post-intervention
Other outcomes:
measure: Changes in Sensory assessment through Quantitative Sensory Testing (QST)
timeFrame: baseline, during the intervention, post-intervention
measure: Changes in sensory acuity
timeFrame: baseline, during the intervention, post-intervention
measure: Changes in reflex
timeFrame: baseline, during the intervention, post-intervention
Locations:
city: Zurich
country: Switzerland
facility: ETH Zurich
Study officials:
affiliation: ETH Zurich
name: Stanisa Raspopovic, Prof. Dr.
role: PRINCIPAL_INVESTIGATOR
References: